Competitor Analysis: PRAME-Targeted Immunotherapy
Competitor Analysis: PRAME-Targeted Immunotherapy
This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non–small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium. It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.
The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non–small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium. It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.
The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) PRAME-TARGETED IMMUNOTHERAPY
PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
PRAME-Selective Cellular & Recombinant Immunotherapies
PRAME-Specific, Multi-Target Adoptive Cell Therapy
2) CORPORATE & INSITUTIONAL PRAME IMMUNOTHERAPY R&D PIPELINES
PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
PRAME-Selective Cellular & Recombinant Immunotherapies
PRAME-Specific, Multi-Target Adoptive Cell Therapy
2) CORPORATE & INSITUTIONAL PRAME IMMUNOTHERAPY R&D PIPELINES
